ARS Pharmaceuticals (SPRY) Interest & Investment Income (2021 - 2026)
ARS Pharmaceuticals (SPRY) reported Interest & Investment Income of -$221000.0 for Q1 2026, down 49.32% on a YoY basis from -$436106.7 in Q1 2025, and down 267.42% sequentially from $132000.0 in Q4 2025.
ARS Pharmaceuticals (SPRY) Interest & Investment Income (2021 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 6 years of Interest & Investment Income data on file, last reported at -$221000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 49.32% year-over-year to -$221000.0; the trailing twelve-month figure through Mar 2026 stood at -$168000.0 (down 185.71% YoY), and the FY2025 full-year result was -$95000.0, down 155.56% from the prior year.
- Interest & Investment Income eased to -$221000.0 in Q1 2026, from $132000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $484000.0 in Q3 2024 to a low of -$339000.0 in Q1 2023.
- A 5-year average of -$6857.1 and a median of -$69500.0 in 2024 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income jumped 2447.37% in 2024 and plunged 461.9% in 2025, its largest moves.
- Tracing SPRY's Interest & Investment Income over 5 years: stood at $407000.0 in 2022, then plunged by 48.4% to $210000.0 in 2023, then plunged by 156.67% to -$119000.0 in 2024, then soared by 210.92% to $132000.0 in 2025, then slumped by 267.42% to -$221000.0 in 2026.
- Business Quant data shows SPRY's Interest & Investment Income at -$221000.0 in Q1 2026, $132000.0 in Q4 2025, and $39000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | ARS Pharmaceuticals | 576.91 Mn | 375.94 Mn | - | -221,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -221,000.00 |
| Dec 31, 2025 | 132,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Jun 30, 2025 | -118,000.00 |
| Mar 31, 2025 | -148,000.00 |
| Dec 31, 2024 | -119,000.00 |
| Sep 30, 2024 | 484,000.00 |
| Jun 30, 2024 | -21,000.00 |
| Mar 31, 2024 | -173,000.00 |
| Dec 31, 2023 | 210,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Jun 30, 2023 | -248,000.00 |
| Mar 31, 2023 | -339,000.00 |
| Dec 31, 2022 | 407,000.00 |
| Dec 31, 2021 | 34,000.00 |
| Sep 30, 2021 | -34,000.00 |